$7.64 Million in Sales Expected for STRATA Skin Sciences Inc (SSKN) This Quarter
Wall Street brokerages expect STRATA Skin Sciences Inc (NASDAQ:SSKN) to report $7.64 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for STRATA Skin Sciences’ earnings. The highest sales estimate is $7.67 million and the lowest is $7.60 million. STRATA Skin Sciences reported sales of $7.48 million in the same quarter last year, which would suggest a positive year over year growth rate of 2.1%. The business is scheduled to announce its next earnings report before the market opens on Tuesday, November 13th.
On average, analysts expect that STRATA Skin Sciences will report full-year sales of $29.70 million for the current year, with estimates ranging from $29.40 million to $30.00 million. For the next fiscal year, analysts anticipate that the firm will post sales of $34.15 million, with estimates ranging from $33.80 million to $34.50 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow STRATA Skin Sciences.
STRATA Skin Sciences (NASDAQ:SSKN) last released its earnings results on Monday, August 13th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.01. The company had revenue of $7.53 million during the quarter, compared to analyst estimates of $6.84 million. STRATA Skin Sciences had a negative return on equity of 27.01% and a negative net margin of 63.07%.
Several hedge funds have recently added to or reduced their stakes in the company. EAM Investors LLC bought a new position in shares of STRATA Skin Sciences in the third quarter valued at approximately $830,000. Macquarie Group Ltd. lifted its stake in STRATA Skin Sciences by 89.7% in the second quarter. Macquarie Group Ltd. now owns 134,033 shares of the medical device company’s stock valued at $275,000 after purchasing an additional 63,393 shares during the last quarter. Nantahala Capital Management LLC purchased a new position in STRATA Skin Sciences in the second quarter valued at approximately $4,261,000. Renaissance Technologies LLC lifted its stake in STRATA Skin Sciences by 164.6% in the second quarter. Renaissance Technologies LLC now owns 293,499 shares of the medical device company’s stock valued at $602,000 after purchasing an additional 182,579 shares during the last quarter. Finally, Menora Mivtachim Holdings LTD. purchased a new position in STRATA Skin Sciences in the second quarter valued at approximately $1,138,000. 27.48% of the stock is owned by institutional investors.
SSKN stock opened at $2.86 on Wednesday. The company has a market capitalization of $80.55 million, a PE ratio of 1.45 and a beta of 0.82. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.77 and a quick ratio of 4.20. STRATA Skin Sciences has a 12-month low of $1.06 and a 12-month high of $3.88.
About STRATA Skin Sciences
STRATA Skin Sciences, Inc, a medical technology company, focuses on the therapeutic and aesthetic dermatology market. The company operates through three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment, and Dermatology Imaging. Its products include XTRAC laser and VTRAC excimer lamp systems used for the treatment of psoriasis, vitiligo, and other skin conditions; the STRATAPEN MicroSystems, a micropigmentation device; and Nordlys, a multi-technology aesthetic laser device for treating vascular and pigmented lesions.
See Also: Inflation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.